Etrolizumab for ulcerative colitis: beyond what meets the eye

Manasi Agrawal¹, Bram Verstockt²

Affiliations

¹ The Dr Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Molecular Prediction of Inflammatory Bowel Disease, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.
² Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven 49 3000, Belgium; Translational Research in Gastrointestinal Disorders-IBD, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium. Electronic address: bram.verstockt@uzleuven.be.

PMID: 34798035
DOI: 10.1016/S2468-1253(21)00369-1

Comment

Etrolizumab for ulcerative colitis: beyond what meets the eye

Manasi Agrawal et al. Lancet Gastroenterol Hepatol. 2022 Jan.

. 2022 Jan;7(1):2-4.

doi: 10.1016/S2468-1253(21)00369-1. Epub 2021 Nov 17.

Authors

Manasi Agrawal¹, Bram Verstockt²

Affiliations

¹ The Dr Henry D Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Center for Molecular Prediction of Inflammatory Bowel Disease, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.
² Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven 49 3000, Belgium; Translational Research in Gastrointestinal Disorders-IBD, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium. Electronic address: bram.verstockt@uzleuven.be.

PMID: 34798035
DOI: 10.1016/S2468-1253(21)00369-1

No abstract available

PubMed Disclaimer

Comment on

Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
Rubin DT, Dotan I, DuVall A, Bouhnik Y, Radford-Smith G, Higgins PDR, Mishkin DS, Arrisi P, Scalori A, Oh YS, Tole S, Chai A, Chamberlain-James K, Lacey S, McBride J, Panés J; HIBISCUS Study Group. Rubin DT, et al. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):17-27. doi: 10.1016/S2468-1253(21)00338-1. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798036 Clinical Trial.
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
Vermeire S, Lakatos PL, Ritter T, Hanauer S, Bressler B, Khanna R, Isaacs K, Shah S, Kadva A, Tyrrell H, Oh YS, Tole S, Chai A, Pulley J, Eden C, Zhang W, Feagan BG; LAUREL Study Group. Vermeire S, et al. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):28-37. doi: 10.1016/S2468-1253(21)00295-8. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798037 Clinical Trial.
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S, Colombel JF, Lukas M, Gisbert JP, D'Haens G, Hayee B, Panaccione R, Kim HS, Reinisch W, Tyrrell H, Oh YS, Tole S, Chai A, Chamberlain-James K, Tang MT, Schreiber S; GARDENIA Study Group. Danese S, et al. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):118-127. doi: 10.1016/S2468-1253(21)00294-6. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798038 Clinical Trial.
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV Jr, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ; HICKORY Study Group. Peyrin-Biroulet L, et al. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):128-140. doi: 10.1016/S2468-1253(21)00298-3. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798039 Clinical Trial.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

K23 DK129762/DK/NIDDK NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Etrolizumab for ulcerative colitis: beyond what meets the eye

Affiliations

Etrolizumab for ulcerative colitis: beyond what meets the eye

Authors

Affiliations

Comment on

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical